A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants
Study Identifier
M24-693
CT.gov Identifier
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete
Study Details
Medical Condition
Study Drug
Phase
Phase 1
Sex
Female & Male
Age
18 - 55 Years
Protocol Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity after single ascending doses (SAD) of ABBV-141 in healthy adult Western and Asian participants.
Study Locations
Location
Status
Location
Acpru /Id# 261162
Grayslake, Illinois, United States, 60030
Status
Not applicable